TR&D2: Development of Novel Hyperpolarized MR Molecular Imaging Probes, Realistic Pre-clinical Models and Correlative Science Methods
TR
基本信息
- 批准号:8935686
- 负责人:
- 金额:$ 31.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:2,4-DinitrophenolAddressAdvisory CommitteesAnimal ModelBicarbonatesBiological AssayBiological ModelsBiologyBiopsy SpecimenBioreactorsCell Culture TechniquesCellsChemicalsCitric Acid CycleCommunitiesConsumptionCorrelative StudyDataDevelopmentEngineeringEnsureFructoseFundingFutureGlutamatesGlutamineGlycolysisGoalsHeterogeneityHumanImageImmune responseLabelLifeMagnetic Resonance ImagingMass Spectrum AnalysisMeasurementMetabolicMetabolismMethodologyMethodsModelingMolecular ProbesMusNeoplasm Circulating CellsNutrientOxidation-ReductionOxygenPathologicPathologyPatient CarePatientsPeer ReviewPerfusionPositron-Emission TomographyPre-Clinical ModelPreparationProceduresProcessProtocols documentationResourcesScienceServicesSiteStaining methodStainsSystemTechniquesTechnologyTestingTissue GraftsTissuesTrainingUnited States National Institutes of Healthbasecostcost effectivenessdesigndriving forceenzyme activityexperienceextracellularhuman diseaseimaging probeimprovedin vivoinnovationinterestmetabolomicsmolecular imagingmouse modelnew technologynovelpre-clinicalsuccesstechnology developmenttissue/cell culturevalidation studies
项目摘要
PROJECT SUMMARY/ABSTRACT
The ten peer-reviewed and NIH funded Collaborative Projects and the eight Service Projects from leading
hyperpolarized MR sites, that are the scientific driving force behind the HMTRC, demonstrate a clear need for
the improved HP probes and techniques, realistic pre-clinical models and correlative pathology and biology
methodologies that will be provided by this TR&D project. TR&D2 builds on our significant experience in the
DNP polarization/dissolution process, the development of new hyperpolarized molecular probe preparations,
and in the development and testing of novel biologically relevant NMR-compatible pre-clinical cell/tissue culture
and associated novel cell/tissue graft murine models. In the current funding cycle, we developed new 13C
labeled HP probes of glycolysis, TCA cycle and cellular redox as well as multi-polarization approaches that
provide simultaneous information on metabolism, perfusion, and extracellular pH (pHe). Through this renewal,
we aim to greatly improve these HP probes and methods with an emphasis on increased sensitivity,
robustness, cost-effectiveness, ease of dissemination, and translatability. This will be accomplished through
the use of glassing agents, chemically optimized new radicals, and polarization methods. We will also
investigate novel HP probes of pHe, ROS and immune response and to address new questions raised by the
CP's (aim 1). In this renewal, we will also investigate new long-lived hyperpolarized probes and use of lower
field MRI scanners in order to prolong the T1's of hyperpolarized probes. In the current project, novel 10 and 5
mm MR and PET compatible 3D cell and tissue culture bioreactors were micro-engineered, robustly and cost-
effectively produced, and extensively tested and validated in cell and tissue culture studies performed in the
CP's. Driven by the needs of the CP's, we now propose future bioreactor designs incorporating new biologic
measurement capabilities, addition of novel cell culture constructs, development of a micro-bioreactor system,
and extension of human cell & tissue bioreactor studies to novel murine models (aim 2). TR&D2 also made
substantial progress developing and implementing procedures to provide correlative pathologic, biologic and
imaging data critical for understanding and validating HP MR findings in the CP's. As requested by the EAC
and CP's, these validation studies will be augmented by the addition of new metabolomics, enzyme activity
staining assays, and PET/HP MR correlative studies (aim 3). While the HP MR probes, model systems and
correlative methodologies have been specifically developed for the CP's through a highly productive push-pull
approach, these technology developments also have significantly benefited the SP's and the HP MR
community in general through extensive dissemination and training as will be continued and expanded through
this renewal.
项目总结/摘要
十个同行评审和NIH资助的合作项目和八个服务项目,
作为HMTRC背后的科学驱动力的超极化MR位点,表明了对以下方面的明确需求:
改进的HP探针和技术,逼真的临床前模型以及相关的病理学和生物学
这将是由这个TR&D项目提供的方法。TR&D2基于我们在以下领域的丰富经验:
DNP极化/溶解过程,新型超极化分子探针制剂的开发,
以及开发和测试新的生物学相关NMR相容的临床前细胞/组织培养物
以及相关的新型细胞/组织移植鼠模型。在当前的融资周期中,我们开发了新的13 C
糖酵解、TCA循环和细胞氧化还原的标记HP探针以及多极化方法,
同时提供代谢、灌注和细胞外pH(pHe)的信息。通过这次更新,
我们的目标是极大地改进这些HP探针和方法,
健壮性、成本效益、易于传播和可翻译性。这将通过以下方式实现:
使用玻璃化剂、化学优化的新自由基和极化方法。我们还将
研究pHe,ROS和免疫应答的新型HP探针,并解决由
CP(目标1)。在这次更新中,我们还将研究新的长寿命超极化探针和使用较低的
场MRI扫描仪,以延长超极化探头的T1。在目前的项目中,小说10和5
mm MR和PET兼容的3D细胞和组织培养生物反应器经过微工程设计,坚固耐用,成本低,
有效地生产,并在细胞和组织培养研究中进行了广泛的测试和验证,
CP的在CP需求的驱动下,我们现在提出了未来的生物反应器设计,
测量能力,添加新的细胞培养结构,开发微型生物反应器系统,
以及将人类细胞和组织生物反应器研究扩展到新的鼠模型(目标2)。TR&D2还
在制定和实施程序以提供相关的病理、生物和
对于理解和验证CP中的HP MR结果至关重要的成像数据。根据选管会的要求
和CP的,这些验证研究将通过增加新的代谢组学,酶活性
染色分析和PET/HP MR相关研究(目的3)。虽然HP MR探头、模型系统和
相关的方法学已经通过一个高生产力的推拉系统,专门为CP开发出来
这些技术的发展也使SP和HP MR受益匪浅
通过广泛的宣传和培训,
这次更新。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John Kurhanewicz其他文献
John Kurhanewicz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John Kurhanewicz', 18)}}的其他基金
High Field MRI For Optimized Translational 1H Multiparametric and Multinuclear Imaging Research
用于优化平移 1H 多参数和多核成像研究的高场 MRI
- 批准号:
10175910 - 财政年份:2021
- 资助金额:
$ 31.64万 - 项目类别:
Preclinical imaging characterization and resource development of PDX SCNC prostate cancer murine models
PDX SCNC 前列腺癌小鼠模型的临床前成像特征和资源开发
- 批准号:
10378320 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
- 批准号:
10669081 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
- 批准号:
10057724 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Characterization of PDX SCNC prostate cancer metastatic murine models and development of associated research resources
PDX SCNC 前列腺癌转移小鼠模型的表征和相关研究资源的开发
- 批准号:
10533469 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
- 批准号:
10470345 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
- 批准号:
10256057 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Co-Clinical Quantitative Imaging of Small Cell Neuroendocrine Prostate Cancer Using Hyperpolarized 13C MRI
使用超极化 13C MRI 对小细胞神经内分泌前列腺癌进行临床联合定量成像
- 批准号:
10737795 - 财政年份:2020
- 资助金额:
$ 31.64万 - 项目类别:
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
肾细胞癌患者来源模型的代谢成像比较
- 批准号:
9753176 - 财政年份:2017
- 资助金额:
$ 31.64万 - 项目类别:
Metabolic imaging comparisons of patient-derived models of renal cell carcinoma
肾细胞癌患者来源模型的代谢成像比较
- 批准号:
10227078 - 财政年份:2017
- 资助金额:
$ 31.64万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 31.64万 - 项目类别:
Research Grant